Exelixis has rounded up slightly more than $71 million on the close of its public offering. Just days before the offering Exelixis reported encouraging interim data from an ongoing Phase II trial evaluating XL647 as first-line therapy for patients with non-small cell lung cancer, with 60 percent of evaluable patients experiencing clinical benefit as their best response.
- see this releaseÂ on the offering
Cancer therapy gets accelerated review at Exelixis. Report
Adverse events force delay in Exelixis trial. Report
Exelixis to collaborate with Genentech. Report
Exelixis signs $157M deal to license hormone receptor. Report